News | February 16, 2009

Clinic Reduces Treatment Time by 75 Percent Using TomoTherapy System

February 16, 2009 - University Clinic Heidelberg, Germany reduces treatment times for the TomoTherapy Hi·Art system from between 40 to 75 percent, while at the same time improving plan quality by further reducing radiation dose to normal tissue.
Based on an in-depth planning study, University Clinic Heidelberg researchers anticipate that a reduction in treatment time of between 40 to 75 percent will be possible with next-generation delivery techniques currently in development by TomoTherapy. Detailed findings of the study will be published later this year.
University Clinic Heidelberg installed the Hi·Art treatment system in March 2006. In December 2008, the medical team, led by professor Jürgen Debus, M.D., professor Klaus Herfarth, M.D., and Florian Sterzing, M.D., treated its 500th cancer patient with TomoTherapy’s unique CT platform-based solution for image-guided, intensity-modulated radiation therapy (IG-IMRT).
“TomoTherapy is used in our clinic to treat a wide range of cancer cases. Because of its advanced capabilities over conventional linear accelerators, the system plays an important role for indications where a large volume is to be irradiated and avoidance of critical structures is paramount,” said Dr. Sterzing. “These cases can require longer treatment times to gain optimal results. However, with the advanced TomoTherapy delivery technique, our research indicates that we should be able to treat these most complex cases in as little as 25 percent of the time necessary now. This is with no compromise in the excellent plan quality to which we are accustomed. In fact, we believe treatment quality will be improved.”
Emphasizing that the enhancements will not just benefit cases involving large or complex tumors, Dr. Sterzing added: “Any treatment you do at the moment will likely be faster, and of even higher quality.”

For more information: and

Related Content

Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Elekta Introduces Strategy for Precision Radiation Medicine at ASTRO 2018

Elekta SmartClinic is one of the key features in the Mosaiq Plaza suite of data-focused integrative oncology software

News | Radiation Therapy | October 30, 2018
At the American Society for Radiation Oncology (ASTRO) Annual Meeting, Oct. 21-24 in San Antonio, Elekta introduced the...
ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | October 05, 2018
October 5, 2018 — Leading oncology experts from around the world recently met to discuss the integration of...
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
IBA Completes Installation of Two Proteus One Proton Therapy Systems in Japan
News | Proton Therapy | July 30, 2018
IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
ViewRay Unveils New Soft Tissue Visualization Technologies for MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | April 30, 2018
ViewRay Inc. announced new magnetic resonance imaging (MRI) technologies under development for its MRIdian Linac...